Papers/PMID:23909402
Potential inhibitory effects of L-carnitine supplementation on tissue advanced glycation end products in patients with hemodialysis.
Rejuvenation research2013The record
3 findings · 1 compound · 3 endpoints
What it reported
How to read these marksWhat moved
3 findings
(R)-carnitine — decreases alanine aminotransferase
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“Oral L-carnitine supplementation for 6 months significantly increased low-density lipoprotein cholesterol (LDL-C), triglycerides, total, free, and acyl carnitine levels, while it decreased alanine transaminase, acyl/free carnitine ratio, β₂-microglobulin, and skin AGE values.”
Quoted verbatim from Potential inhibitory effects of L-carnitine supplementation on tissue advanced glycation end products in patients with hemodialysis.. - Study
- RCT
- Duration
- 6 months
- Dose
- 900 mg/day oral
- Population
- Hemodialysis patients with carnitine deficiency (total carnitine below 50 μmol/L), randomized to L-carnitine or control
Potential inhibitory effects of L-carnitine supplementation on tissue advanced glycation end products in patients with hemodialysis.2013PMID:23909402Permalink
(R)-carnitine — increases LDL cholesterol
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“Oral L-carnitine supplementation for 6 months significantly increased low-density lipoprotein cholesterol (LDL-C), triglycerides, total, free, and acyl carnitine levels, while it decreased alanine transaminase, acyl/free carnitine ratio, β₂-microglobulin, and skin AGE values.”
Quoted verbatim from Potential inhibitory effects of L-carnitine supplementation on tissue advanced glycation end products in patients with hemodialysis.. - Study
- RCT
- Duration
- 6 months
- Dose
- 900 mg/day oral
- Population
- Hemodialysis patients with carnitine deficiency (total carnitine below 50 μmol/L), randomized to L-carnitine or control
Potential inhibitory effects of L-carnitine supplementation on tissue advanced glycation end products in patients with hemodialysis.2013PMID:23909402Permalink
(R)-carnitine — increases triglycerides
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“Oral L-carnitine supplementation for 6 months significantly increased low-density lipoprotein cholesterol (LDL-C), triglycerides, total, free, and acyl carnitine levels, while it decreased alanine transaminase, acyl/free carnitine ratio, β₂-microglobulin, and skin AGE values.”
Quoted verbatim from Potential inhibitory effects of L-carnitine supplementation on tissue advanced glycation end products in patients with hemodialysis.. - Study
- RCT
- Duration
- 6 months
- Dose
- 900 mg/day oral
- Population
- Hemodialysis patients with carnitine deficiency (total carnitine below 50 μmol/L), randomized to L-carnitine or control
Potential inhibitory effects of L-carnitine supplementation on tissue advanced glycation end products in patients with hemodialysis.2013PMID:23909402Permalink